Metastatic Colorectal Cancer and Type 2 Diabetes: Prognostic and Genetic Interactions

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2021 Oct 20

PMID 34668636

Citations 13

Authors

Alessandro Ottaiano

Luisa Circelli

Mariachiara Santorsola

Giovanni Savarese

Daniela Fontanella

Valerio Gigantino

Annabella Di Mauro

Silvia Zappavigna

Angela Lombardi

Francesco Perri

Marco Cascella

Vincenza Granata

Maurizio Capuozzo

Guglielmo Nasti

Michele Caraglia

Affiliations

Soon will be listed here.

Abstract

The present study was undertaken to analyze prognostic and genetic interactions between type 2 diabetes and metastatic colorectal cancer. Patients' survival was depicted through the Kaplan-Meier product limit method. Prognostic factors were examined through the Cox proportional-hazards regression model, and associations between diabetes and clinical-pathologic variables were evaluated by the χ test. In total, 203 metastatic colorectal cancer patients were enrolled. Lymph nodes (P = 0.0004) and distant organs (> 2 distant sites, P = 0.0451) were more frequently involved in diabetic patients compared with those without diabetes. Diabetes had an independent statistically significant negative prognostic value for survival. Highly selected patients with cancer and/or diabetes as their only illness(es) were divided into three groups: (a) seven oligo-metastatic patients without diabetes, (b) 10 poly-metastatic patients without diabetes, and (c) 12 poly-metastatic diabetic patients. These groups of patients were genetically characterized through the Illumina NovaSeq 6000 (San Diego, CA, USA) platform and TruSigt™Oncology 500 kit, focusing on genes involved in diabetes and colorectal cancer. Gene variants associated with diabetes and cancer were more frequent in patients in group 3. We found that type 2 diabetes is a negative prognostic factor for survival in colorectal cancer. Diabetes-associated gene variants could concur with malignancy, providing a rational basis for innovative models of tumor progression and therapy.

Citing Articles

Effects of T2DM on postoperative outcome of patients with colorectal cancer: a study on the relationship between blood glucose control and survival rate.

Wu K, Shi Q, Cui G, Xu Y, Yu H, Li Q Am J Cancer Res. 2024; 14(4):1892-1903.

PMID: 38726261 PMC: 11076264. DOI: 10.62347/HTRZ8589.

Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.

Ottaiano A, Santorsola M, Diana A, Belli A, Lentini Graziano M, Orefice J Cancer Med. 2024; 13(4):e6892.

PMID: 38457226 PMC: 10923031. DOI: 10.1002/cam4.6892.

Patterns and trends of mortality from metastatic colorectal cancer in Shanghai, China from 2005 to 2021: a population-based retrospective analysis.

Cheng X, Zhou J, Chen Y, Zhao Y, Zheng H, Wang Q J Cancer Res Clin Oncol. 2024; 150(2):68.

PMID: 38305905 PMC: 10837271. DOI: 10.1007/s00432-023-05518-z.

Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment.

Santorsola M, Capuozzo M, Savarese G, Ianniello M, Petrillo N, Casillo M Genes (Basel). 2023; 14(12).

PMID: 38136953 PMC: 10742616. DOI: 10.3390/genes14122131.

Effects of potentilla discolor bunge extracts on oxidative stress and glycolipid metabolism in animal models of diabetes: a systematic review and meta-analysis.

Yang Y, Deng W, Wu Y, Zi C, Chen Q Front Pharmacol. 2023; 14:1218757.

PMID: 37849729 PMC: 10577192. DOI: 10.3389/fphar.2023.1218757.

References

Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder H . Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer. 2004; 114(1):58-73. DOI: 10.1002/ijc.20645. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

Frayling T . Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet. 2007; 8(9):657-62. DOI: 10.1038/nrg2178. View

Djiogue S, Nwabo Kamdje A, Vecchio L, Kipanyula M, Farahna M, Aldebasi Y . Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2012; 20(1):R1-R17. DOI: 10.1530/ERC-12-0324. View

Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S . Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020; 162:108072. DOI: 10.1016/j.diabres.2020.108072. View

Yang H, Robinson P, Wang K . Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods. 2015; 12(9):841-3. PMC: 4718403. DOI: 10.1038/nmeth.3484. View

Abel E, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E . HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife. 2018; 7. PMC: 6122955. DOI: 10.7554/eLife.33947. View

Acevedo A, Diaz Y, Perez C, Garau M, Baron J, Cruz-Correa M . Diabetes Mellitus and Colorectal Neoplasia. J Cancer Ther. 2013; 3(6A):859-865. PMC: 3614367. DOI: 10.4236/jct.2012.326110. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

10.

Grarup N, Rose C, Andersson E, Andersen G, Nielsen A, Albrechtsen A . Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes. 2007; 56(12):3105-11. DOI: 10.2337/db07-0856. View

11.

Wu H, Zhang J, Zhou B . Metabolic syndrome and colorectal adenoma risk: A systematic review and meta‑analysis. Clin Res Hepatol Gastroenterol. 2021; 45(5):101749. DOI: 10.1016/j.clinre.2021.101749. View

12.

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

13.

Riera P, Rodriguez-Santiago B, Lasa A, Gonzalez-Quereda L, Martin B, Salazar J . Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020; 12(8). PMC: 7463997. DOI: 10.3390/cancers12082245. View

14.

Mills K, Bellows C, Hoffman A, Kelly T, Gagliardi G . Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013; 56(11):1304-19. PMC: 3800045. DOI: 10.1097/DCR.0b013e3182a479f9. View

15.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L . Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. Oncotarget. 2017; 8(18):30606-30616. PMC: 5444769. DOI: 10.18632/oncotarget.16725. View

16.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Petrelli F, Ghidini M, Rausa E, Ghidini A, Cabiddu M, Borgonovo K . Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. Can J Diabetes. 2020; 45(2):186-197.e2. DOI: 10.1016/j.jcjd.2020.06.009. View

19.

Ali Khan U, Fallah M, Tian Y, Sundquist K, Sundquist J, Brenner H . Personal History of Diabetes as Important as Family History of Colorectal Cancer for Risk of Colorectal Cancer: A Nationwide Cohort Study. Am J Gastroenterol. 2020; 115(7):1103-1109. DOI: 10.14309/ajg.0000000000000669. View

20.

Amadou A, Freisling H, Jenab M, Tsilidis K, Trichopoulou A, Boffetta P . Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium. Br J Cancer. 2021; 124(11):1882-1890. PMC: 8144608. DOI: 10.1038/s41416-021-01347-4. View